Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity

International Journal of Pharmaceutics

Volumn 355, Issue 1-2, 2008, Pages 314-320

  Huang, Guihua ^a   Zhang, Na ^a   Bi, Xiuli ^a   Dou, Mingjin ^b  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Tumour Hospital   (China)

Author keywords

Body distribution; Drug targeting; Solid lipid nanoparticles; Sustained release system; Temozolomide

Indexed keywords

SOLID LIPID NANOPARTICLE; TEMOZOLOMIDE;

AREA UNDER THE CURVE; ARTICLE; BRAIN; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMISTRY, PHYSICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DACARBAZINE; DATA INTERPRETATION, STATISTICAL; DRUG CARRIERS; HEART DISEASES; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MICE; NANOPARTICLES; RABBITS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 41349095417     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.12.013     Document Type: Article

References (16)

1. Allen T.M., and Cullis P.R. Drug delivery systems: entering the mainstream. Science 303 (2004) 1818-1822
2. Cavalli R., Morel S., Gasco M.R., Chetoni P., and Saettone M.F. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int. J. Pharm. 117 (1995) 243-246
3. Couvreur P., Dubernet C., and Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41 (1995) 2-13
4. Du X.L. Temozolomide: a new drug for the treatment of intractable and polymorphism glioma. Chin. Pharm. J. 35 (2000) 135
5. Illum S.L., and Davis S.S. Effect of the nonionic surfactant Poloxamer338 on the fate and deposition of polystyrene microspheres following intravenous administration. J. Pharm. Sci. 72 (1983) 1086-1089
6. Lenaerts V., Akbiri L., Chouinard F., et al. Nanocapsules with a reduced liver uptake: targeting of phthalocyanines to EMT-6 mouse mammary tumour in vivo. Eur. J. Pharm. Biopharm. 41 (1995) 38-43
7. Manjunath K., and Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107 (2005) 215-228
8. Moghimi S.M. Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 16 (1995) 183-193
9. zur Muhlen A., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. J. Pharm. Biopharm. 45 (1998) 149-155
10. Muller R.H., Maassen S., Schwarz C., and Mehnert W. Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes. J. Control. Release 47 (1997) 261-269
11. Muller R.H., Maassen S., Weyhers H., and Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine908 and Poloxamer407. J. Drug Target. 4 (1996) 161-170
12. Muller R.H., Madder K., and Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur. J. Pharm. Biopharm. 50 (2000) 161-177
13. Muller R.H., Mehnert W., Lucks J.S., Schwarz C., zur Muhlen A., Weyhers H., Freitas C., and Ruhl D. Solid lipid nanoparticles (SLN): an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41 (1995) 62-69
14. Newlands E.S., Blackledge G.R., Slack J.A., et al. Phase I trial of temozolomide. Br. J. Cancer 65 (1992) 287-291
15. Newlands E.S., Stevens M.F., Wedge S.R., et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev. 23 (1997) 35-61
16. Yang S.C., Lu L.F., Cai Y., Zhu J.B., Liang B.W., and Yang C.Z. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release 59 (1999) 299-307